SCHEMBL9866682

SCHEMBL9866682

N=C(NCCCc1c[nH]cn1)NCC(O)COc1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 5/20 0.47
ADRB1 P08588 5/20 0.47
NR2E1 Q9Y466 5/20 0.47
SIGMAR1 Q99720 4/20 0.47
CYP1A2 P05177 4/20 0.47
CYP2D6 P10635 4/20 0.47
ADRB3 P13945 4/20 0.47
SLC6A4 P31645 3/20 0.47
HTR2B P41595 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HTR2A P28223 3/20 0.47
HTR2C P28335 3/20 0.47
HTR6 P50406 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPK1 P28482 3/20 0.47
SCN1A P35498 2/20 0.47
SLC10A1 Q14973 2/20 0.47
SCN2A Q99250 2/20 0.47
SCN3A Q9NY46 2/20 0.47
HTR1A P08908 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9866059 0.85 ADRB1 (0.41) ADRB2ADRB1CYP1A2CYP2D6ADRB3
SCHEMBL9865763 0.77 ADRB1 (0.44) ADRB2ADRB1NR2E1SIGMAR1CYP1A2
SCHEMBL9866679 0.74 PRMT5 (0.45) LMNA
SCHEMBL9866779 0.73 CYP1A2 (0.41) SIGMAR1CYP1A2CYP2D6ALDH1A1SMN1; SMN2
SCHEMBL9867117 0.73 L3MBTL1 (0.43) SIGMAR1CYP2D6CYP2C9KMT2AKDM4E
SCHEMBL9867346 0.72 HRH3 (0.45) SMN1; SMN2HTR1BDRD3MEN1KMT2A
SCHEMBL11036952 0.72 HRH2 (0.30)
SCHEMBL9865953 0.71 HRH3 (0.44) SMN1; SMN2TSHRHTR1BDRD3MEN1
SCHEMBL9709892 0.71 KDM1A (0.40) ALDH1A1SMN1; SMN2MAPK1LMNAKCNH2
SCHEMBL9828126 0.71 EPHX2 (0.39) SIGMAR1HTR2AHTR1BKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5021431-A H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion HEUMANN PHARMA GMBH & CO. (DE) 1991-06-04 US disclosed
EP-0199845-B1 IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HEUMANN PHARMA GMBH & CO (DE) 1990-08-01 EP disclosed
EP-0199845-A1 Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them HEUMANN PHARMA GMBH & CO (DE) 1986-11-05 EP disclosed